drugset / Trial / NCT01915667

Oral Bioavailability of Two Solid Formulations of GLPG0634

NCT01915667

Phase 1 Completed 12 enrolled Lakefront Biotherapeutics NV
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to evaluate the amount of compound present in the blood (relative bioavailability) after a single administration of GLPG0634 as a tablet versus a capsule in fasted conditions in male healthy subjects. Also, the effect of food on the bioavailability of the tablet formulation will be studied as well as the safety and tolerability of single oral doses of GLPG0634 given either as capsule or tablet.

Timeline

Start
2013-07
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Filgotinib Small molecule 200 mg Oral

Indications

No indication recorded.